Your browser doesn't support javascript.
loading
DFL23448, A Novel Transient Receptor Potential Melastin 8-Selective Ion Channel Antagonist, Modifies Bladder Function and Reduces Bladder Overactivity in Awake Rats.
Mistretta, Francesco A; Russo, Andrea; Castiglione, Fabio; Bettiga, Arianna; Colciago, Giorgia; Montorsi, Francesco; Brandolini, Laura; Aramini, Andrea; Bianchini, Gianluca; Allegretti, Marcello; Bovolenta, Silvia; Russo, Roberto; Benigni, Fabio; Hedlund, Petter.
Affiliation
  • Mistretta FA; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Russo A; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Castiglione F; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Bettiga A; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Colciago G; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Montorsi F; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Brandolini L; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Aramini A; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Bianchini G; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Allegretti M; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Bovolenta S; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Russo R; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Benigni F; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
  • Hedlund P; Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy (F.A.M., A.R., F.C., A.B., G.C., F.M., F.B., P.H.); Department of Clinical and Experimental Pharmacology, Lund University, Lund, Sweden (F.A.M., P.H.); Università Vita-Salute San Raffaele,
J Pharmacol Exp Ther ; 356(1): 200-11, 2016 Jan.
Article in En | MEDLINE | ID: mdl-26546575
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Thiazoles / Urinary Bladder / TRPM Cation Channels / Urinary Bladder, Overactive Limits: Animals / Female / Humans / Male Language: En Journal: J Pharmacol Exp Ther Year: 2016 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetrazoles / Thiazoles / Urinary Bladder / TRPM Cation Channels / Urinary Bladder, Overactive Limits: Animals / Female / Humans / Male Language: En Journal: J Pharmacol Exp Ther Year: 2016 Document type: Article Country of publication: United States